Study guide

11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

Key Takeaways Explain This Topic AI

Substance Use Disorders (SUD) are diagnosed via DSM-5-TR criteria spanning 11 symptoms across 4 functional domains (Impaired control, Social impairment, Risky use, Pharmacological criteria [tolerance/withdrawal]), stratified by severity into Mild (2–3), Moderate (4–5), and Severe (≥6 criteria over a 12-month period).

Alcohol Use Disorder (AUD) screening in primary care utilizes AUDIT-C (positive if ≥4 in men, ≥3 in women/older adults) and CAGE; acute alcohol withdrawal is monitored via CIWA-Ar and treated with symptom-triggered benzodiazepines (lorazepam or oxazepam preferred in hepatic impairment/cirrhosis ['LOT' drugs bypass phase I hepatic oxidation]); chronic relapse prevention pharmacotherapy includes Naltrexone (first-line; opioid antagonist reducing cravings/heavy drinking, contraindicated in acute hepatitis/liver failure or opioid use) and Acamprosate (first-line in liver impairment/cirrhosis; contraindicated in severe renal disease CrCl <30 mL/min).

Wernicke Encephalopathy (acute triad: confusion, ophthalmoplegia/nystagmus, ataxia) is a medical emergency caused by thiamine (Vitamin B1) deficiency; high-dose parenteral thiamine (100–500 mg) must ALWAYS be administered PRIOR to or concurrent with IV dextrose to avoid precipitating acute irreversible Korsakoff psychosis (anterograde/retrograde amnesia with confabulation).

Opioid Use Disorder (OUD) is treated with Medication for Opioid Use Disorder (MOUD): Buprenorphine/Naloxone (Suboxone; partial mu-agonist with high receptor affinity; initiation requires objective mild-to-moderate withdrawal [COWS score ≥8–12] to avoid precipitated withdrawal), Methadone (full mu-agonist in certified OTPs; monitor QTc), or Extended-Release Naltrexone (Vivitrol IM monthly; requires mandatory 7–14 day complete opioid-free washout); universal co-prescription of Naloxone nasal spray (Narcan) is standard harm reduction.

Cannabis Hyperemesis Syndrome (CHS) occurs in chronic daily cannabis users, characterized by cyclical nausea, intractable vomiting, and severe colicky abdominal pain characteristically relieved by compulsive hot baths/showers (TRPV1 receptor activation); acute management utilizes topical capsaicin cream and haloperidol, with complete and permanent cannabis cessation representing the definitive cure.

Last updated: August 2026

Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

Substance use disorders (SUDs) represent chronic, relapsing brain diseases that intersect with every domain of adult and geriatric primary care. The Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) plays a pivotal role in routine universal screening, early brief intervention, medical detoxification triage, evidence-based medication-assisted treatment, overdose prevention, and harm reduction.

Mastering substance use disorders requires an in-depth appreciation of mesolimbic reward neurobiology, fluency in DSM-5-TR diagnostic criteria, mastery of withdrawal staging and prophylaxis (including the prevention of Wernicke-Korsakoff syndrome), and disciplined prescribing of medications for alcohol, tobacco, and opioid use disorders.

  • 1. Neurobiology of Addiction & The SBIRT Framework
  • The Mesolimbic Dopamine Reward Pathway

All addictive substances share a common final neurobiological mechanism: the supraphysiological surge of dopamine release in the Nucleus Accumbens (NAc) via dopaminergic projections originating from the Ventral Tegmental Area (VTA) . +-----------------------------------------------------------------------------+

  • | THE THREE-STAGE CYCLE OF ADDICTION |
  • | |
  • | 1. BINGE / INTOXICATION (Basal Ganglia & Nucleus Accumbens) |
  • | - Acute dopamine and opioid peptide release -> Euphoria, positive |
  • | reinforcement, and incentive salience ("wanting" vs "liking"). |
  • | | |
  • | v |
  • | 2. WITHDRAWAL / NEGATIVE AFFECT (Extended Amygdala & Habenula) |
  • | - Chronic downregulation of D2 dopamine receptors (anhedonia). |
  • | - Recruitment of stress neurotransmitters: Corticotropin-Releasing |
  • | Factor (CRF), Dynorphin, and Norepinephrine -> Dysphoria, anxiety, |
  • | irritability, and physical withdrawal (negative reinforcement). |
  • | | |
  • | v |
  • | 3. PREOCCUPATION / ANTICIPATION (Prefrontal Cortex & Hippocampus) |
  • | - "Craving Circuit": Glutamatergic projections from Prefrontal Cortex |
  • | and Basolateral Amygdala drive compulsive drug-seeking behavior and |
  • | loss of executive inhibitory self-control ("hypofrontality"). |
  • +-----------------------------------------------------------------------------+
  • The SBIRT Protocol in Primary Care

SBIRT (Screening, Brief Intervention, and Referral to Treatment) is an evidence-based public health framework validated for early identification and intervention in primary care settings:

Screening (S): Universal screening using standardized, validated questionnaires (e.g., AUDIT-C for alcohol, Single-Question Screening for drugs/tobacco) at annual preventive health visits.

Brief Intervention (BI): A 5-to-15-minute structured motivational dialogue using Motivational Interviewing (MI) techniques ( OARS: Open-ended questions, Affirmations, Reflective listening, Summaries ) to enhance the patient's intrinsic motivation to modify substance use.

Referral to Treatment (RT): Facilitating seamless connection to specialty addiction medicine, intensive outpatient programs (IOP), residential rehabilitation, or peer-led recovery networks (AA, NA, SMART Recovery) for patients with moderate-to-severe substance use disorders.

2. DSM-5-TR Diagnostic Criteria for Substance Use Disorder

Under DSM-5-TR, substance abuse and substance dependence are unified into a single diagnosis: Substance Use Disorder (SUD) . Diagnosis requires meeting ≥ 2 \ge 2 ≥ 2 of the following 11 criteria over a 12-month period , categorized into 4 functional domains: +-----------------------------------------------------------------------------+

  • | DSM-5-TR 11 DIAGNOSTIC CRITERIA |
  • | |
  • | DOMAIN 1: IMPAIRED CONTROL |
  • | 1. Consuming substance in larger amounts or over longer period than intended|
  • | 2. Persistent desire or unsuccessful efforts to cut down or control use |
  • | 3. Great deal of time spent obtaining, using, or recovering from substance|
  • | 4. CRAVING: Intense urge or desire to use the substance |
  • | |
  • | DOMAIN 2: SOCIAL IMPAIRMENT |
  • | 5. Recurrent use resulting in failure to fulfill major role obligations |
  • | at work, school, or home |
  • | 6. Continued use despite persistent/recurrent social or interpersonal probs|
  • | 7. Important social, occupational, or recreational activities given up |
  • | |
  • | DOMAIN 3: RISKY USE |
  • | 8. Recurrent use in physically hazardous situations (e.g., driving) |
  • | 9. Continued use despite knowledge of physical or psychological problem |
  • | caused or exacerbated by the substance |
  • | |
  • | DOMAIN 4: PHARMACOLOGICAL CRITERIA |
  • | 10. TOLERANCE: Need for markedly increased amounts to achieve intoxication |
  • | 11. WITHDRAWAL: Characteristic withdrawal syndrome or substance taken to |
  • | relieve/avoid withdrawal symptoms |
  • | *(Note: Tolerance and withdrawal do NOT count toward diagnosis when taken |
  • | under appropriate medical supervision, e.g., prescribed opioids/benzos!)|
  • | ----------------------------------------------------------------------- |
  • | SEVERITY STRATIFICATION: |
  • | * MILD: 2 to 3 criteria |
  • | * MODERATE: 4 to 5 criteria |
  • | * SEVERE: 6 or more criteria |
  • +-----------------------------------------------------------------------------+
  • 3. Alcohol Use Disorder (AUD)
  • Primary Care Screening Tools

AUDIT-C (Alcohol Use Disorders Identification Test - Consumption): A validated 3-item questionnaire scored 0–12 evaluating frequency of drinking, quantity consumed, and binge drinking ( ≥ 6 \ge 6 ≥ 6 drinks on one occasion). Positive screen: ≥ 4 \ge 4 ≥ 4 in adult men, ≥ 3 \ge 3 ≥ 3 in women and adults aged ≥ 65 \ge 65 ≥ 65 .

CAGE Questionnaire: Scored 0–4 (Score ≥ 2 \ge 2 ≥ 2 indicates high likelihood of clinically significant alcohol misuse):

C: Have you ever felt you should Cut down on your drinking?

A: Have people Annoyed you by criticizing your drinking?

G: Have you ever felt bad or Guilty about your drinking?

E: Have you ever had an Eye-opener (a drink first thing in the morning to steady nerves or relieve a hangover)?

Clinical Biomarkers of Chronic Heavy Alcohol Ingestion

AST to ALT Ratio ≥ 2 : 1 \ge 2:1 ≥ 2 : 1 : Classic hallmark of alcoholic liver disease (mitochondrial AST release combined with hepatic pyridoxal-5-phosphate depletion suppressing ALT synthesis).

Gamma-Glutamyl Transferase (GGT): Highly sensitive marker of heavy alcohol consumption (inducible enzyme; normalizes over 2–4 weeks of sobriety).

Macrocytosis (Elevated MCV > 100 fL): Direct toxic effect of ethanol on erythropoiesis in the bone marrow (frequently present without anemia or B12/folate deficiency).

Carbohydrate-Deficient Transferrin (CDT): Highly specific biomarker of sustained heavy drinking ( > 4 − 5 >4-5 > 4 − 5 drinks/day for ≥ 2 \ge 2 ≥ 2 weeks).

Urine Ethyl Glucuronide (EtG): Direct non-oxidative metabolite of ethanol detectable in urine for up to 3 to 5 days post-ingestion.

Acute Alcohol Withdrawal Syndrome: Staging & Management +---------------------------------------------------------------------------------------------------------+

  • | ALCOHOL WITHDRAWAL TIMELINE & STAGING |
  • | |
  • | WITHDRAWAL STAGE ONSET POST-LAST DRINK HALLMARK CLINICAL SIGNS & SYMPTOMS |
  • | --------------------------------------------------------------------------------------------------- |
  • | Stage 1: Minor 6 to 12 hours * Fine resting tremor, anxiety, diaphoresis, |
  • | Withdrawal palpitations, insomnia, headache, mild nausea. |
  • | * Intact sensorium and orientation. |
  • | |
  • | Stage 2: Alcoholic 12 to 24 hours * Visual, auditory, or tactile hallucinations / |
  • | Hallucinosis illusions (e.g., seeing insects, hearing voices). |
  • | * CRITICAL: SENSORIUM IS COMPLETELY CLEAR! |
  • | Patient is alert and oriented (unlike DTs!). |
  • | |
  • | Stage 3: Withdrawal 24 to 48 hours * Generalized tonic-clonic seizures. Single or brief |
  • | Seizures ("Rum Fits") burst of 2-3 seizures. |
  • | * ~30% of untreated patients progress to DTs. |
  • | |
  • | Stage 4: DELIRIUM 48 to 96 hours * MEDICAL EMERGENCY (5-15% mortality if untreated!). |
  • | TREMENS (DTs) (can last up to 5-7 days) * PROFOUND DELIRIUM: Severe fluctuating confusion, |
  • | disorientation, agitation, visual hallucinations. |
  • | * SEVERE AUTONOMIC INSTABILITY: Extreme tachycardia, |
  • | hypertension, marked diaphoresis, fever/hyperthermia|
  • +---------------------------------------------------------------------------------------------------------+

CIWA-Ar Protocol & Pharmacotherapy of Acute Withdrawal:

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised): Evaluates 10 clinical parameters (nausea/vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, orientation) scored 0–67. A score ≥ 8 − 10 \ge 8-10 ≥ 8 − 10 triggers symptom-triggered benzodiazepine administration .

Benzodiazepine Selection:

Long-Acting (Diazepam, Chlordiazepoxide): Preferred in patients with normal hepatic function due to smoother tapering profile and lower incidence of breakthrough seizures.

Short/Intermediate-Acting ("LOT" Agents: Lorazepam, Oxazepam, Temazepam): MANDATORY DRUGS OF CHOICE in patients with hepatic cirrhosis, acute alcoholic hepatitis, or elderly patients because they undergo direct Phase II glucuronidation and do not rely on Phase I hepatic CYP450 oxidation (avoiding drug accumulation and hepatic encephalopathy!).

Mandatory Wernicke-Korsakoff Syndrome Prevention Protocol:

Wernicke Encephalopathy Triad: (1) Acute encephalopathy / confusion, (2) Oculomotor dysfunction (nystagmus, bilateral lateral rectus / CN VI palsy), and (3) Gait ataxia.

Pathophysiology: Thiamine (Vitamin B 1 B_1 B 1 ​ ) deficiency impairs pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, causing cellular metabolic failure and hemorrhagic necrosis in the mammillary bodies, thalamus, and periaqueductal gray.

MANDATORY CLINICAL RULE: High-dose parenteral Thiamine (100 to 500 mg IV/IM) must ALWAYS be administered PRIOR TO or CONCURRENTLY WITH any IV glucose/dextrose infusions ! Infusing dextrose without thiamine forces remaining thiamine cofactors into the glycolysis cycle, precipitating acute irreversible Wernicke Encephalopathy and progression to Korsakoff Syndrome (irreversible anterograde and retrograde amnesia with prominent confabulation).

Long-Term Relapse Prevention Pharmacotherapy for AUD +---------------------------------------------------------------------------------------------------------+

  • | AUD RELAPSE PREVENTION PHARMACOTHERAPY MATRIX |
  • | |
  • | MEDICATION MECHANISM OF ACTION CLINICAL ADVANTAGES & DOSING CONTRAINDICATIONS & SAFETY|
  • | --------------------------------------------------------------------------------------------------- |
  • | Naltrexone Mu-opioid receptor * FIRST-LINE for reducing * ABSOLUTELY CONTRA- |
  • | (Oral & IM Depo) antagonist. Blocks cravings and heavy drinking INDICATED IN PATIENTS |
  • | endogenous endorphin days. TAKING PRESCRIPTION |
  • | reward from alcohol. * Oral: 50 mg PO daily. OPIOIDS OR WITH ACUTE |
  • | * IM Depo (Vivitrol): HEPATITIS / LIVER |
  • | 380 mg IM monthly (ideal FAILURE! Check baseline |
  • | for poor adherence). LFTs (hepatotoxicity). |
  • | |
  • | Acamprosate Modulates central * FIRST-LINE AGENT OF CHOICE * EXCRETED ENTIRELY BY |
  • | (Campral) glutamatergic (NMDA) and IN PATIENTS WITH HEPATIC KIDNEYS! |
  • | GABAergic neurotransmission;IMPAIRMENT / CIRRHOSIS! * Dose-reduce in moderate|
  • | restores neurochemical * Promotes complete renal impairment. |
  • | balance disrupted by chronic abstinence. * CONTRAINDICATED IN |
  • | ethanol exposure. * Dosing: 666 mg PO TID. SEVERE RENAL FAILURE |
  • | (CrCl < 30 mL/min). |
  • | |
  • | Disulfiram Irreversible inhibitor of * SECOND-LINE AVERSIVE * Must be fully abstinent|
  • | (Antabuse) ALDEHYDE DEHYDROGENASE. THERAPY for highly motivated for >= 12-24 hours! |
  • | Causes rapid accumulation patients with observed * Ingestion of ANY |
  • | of toxic ACETALDEHYDE dosing. alcohol causes severe |
  • | upon any ethanol ingestion. * Dosing: 250-500 mg PO flushing, throbbing |
  • | daily. headache, vomiting, |
  • | hypotension, arrhythmia.|
  • | * Avoid hidden alcohol |
  • | (cough syrups, sauces). |
  • | |
  • | Topiramate GABA-A facilitator and * Off-label second-line; * Cognitive slowing, |
  • | (Off-Label) AMPA/kainate antagonist. reduces heavy drinking. paresthesias, weight loss|
  • | Reduces dopamine release. * Dosing: 25-150 mg PO BID. kidney stones, glaucoma.|
  • +---------------------------------------------------------------------------------------------------------+
  • 4. Tobacco & Nicotine Use Disorder

Tobacco use remains the leading cause of preventable disease, disability, and death in the United States.

The 5 A's Evidence-Based Clinical Model

Ask: Universally identify and document tobacco use status at every clinical visit.

Advise: Strongly urge all tobacco users to quit in a clear, personalized, and non-judgmental manner ( "Quitting smoking is the single most important action you can take to protect your heart and lungs" ).

Assess: Determine willingness and readiness to make a quit attempt within the next 30 days.

Assist: Provide evidence-based pharmacotherapy and behavioral counseling to support the quit attempt.

Arrange: Schedule follow-up contact (in person or via telehealth) within the first week after the established quit date.

Evidence-Based Pharmacotherapy for Smoking Cessation +---------------------------------------------------------------------------------------------------------+

  • | SMOKING CESSATION PHARMACOTHERAPY MATRIX |
  • | |
  • | TREATMENT MODALITY MECHANISM & DOSING CLINICAL ADVANTAGES ADVERSE EFFECTS & PEARLS|
  • | --------------------------------------------------------------------------------------------------- |
  • | Varenicline Alpha-4 Beta-2 nicotinic * HIGHEST MONOTHERAPY * Nausea (take with food|
  • | (Chantix) acetylcholine receptor EFFICACY among all smoking and full glass water). |
  • | PARTIAL AGONIST. cessation drugs! * Insomnia and abnormal/|
  • | - Provides moderate dopamine* Start 1 week BEFORE quit vivid dreams. |
  • | release to reduce cravings. date (titrate: 0.5 mg daily* Historical black box |
  • | - Blocks nicotine binding. to 1 mg BID x 12 weeks). warning for neuro- |
  • | psychiatric risk removed|
  • | |
  • | Combination Nicotine Long-acting Transdermal * SIGNIFICANTLY SUPERIOR TO * Patch: Local skin |
  • | Replacement Therapy PATCH + Short-acting GUM SINGLE-AGENT NRT! irritation, vivid dreams|
  • | (Combination NRT) or LOZENGE for cravings. * Patch Dosing: 21 mg/day (remove patch at bed). |
  • | - Delivers clean nicotine (if >10 cigs/day); * Gum/Lozenge: Hiccups, |
  • | without toxic combustion 14 mg/day (if <=10 cigs/d).* "Chew and park" gum |
  • | carcinogens/tar. * Gum/Lozenge: 2 mg or 4 mg. technique; avoid acid!|
  • | |
  • | Bupropion SR Norepinephrine-Dopamine * Dual utility in patients * ABSOLUTELY CONTRA- |
  • | (Zyban / Wellbutrin) Reuptake Inhibitor (NDRI). with COMORBID DEPRESSION. INDICATED IN SEIZURE |
  • | - Reduces cravings and * Prevents post-cessation DISORDERS, BULIMIA, or |
  • | withdrawal discomfort. weight gain. ANOREXIA NERVOSA! |
  • | * Start 1-2 weeks before quit* Insomnia, dry mouth, |
  • | (150 mg daily x 3d -> BID). agitation. |
  • +---------------------------------------------------------------------------------------------------------+
  • 5. Opioid Use Disorder (OUD) & Harm Reduction
  • Medications for Opioid Use Disorder (MOUD)

MOUD is the gold-standard medical therapy for OUD, proven to reduce illicit opioid use, decrease overdose mortality by > 50 % >50\% > 50% , reduce transmission of HIV and Hepatitis C, and improve treatment retention. +---------------------------------------------------------------------------------------------------------+

  • | MEDICATIONS FOR OPIOID USE DISORDER (MOUD) |
  • | |
  • | MEDICATION PHARMACOLOGICAL CLASS REGULATORY & CLINICAL RULES ADVERSE EFFECTS & PEARLS|
  • | --------------------------------------------------------------------------------------------------- |
  • | Buprenorphine / PARTIAL MU-OPIOID AGONIST * Can be prescribed in any * HIGH AFFINITY / CEILING|
  • | Naloxone (Suboxone) with high receptor affinity standard office-based primary EFFECT: Minimal risk |
  • | + Kappa antagonist. care setting (X-waiver no of respiratory depression|
  • | * Co-formulated with longer required!). as a single agent. |
  • | naloxone (4:1 ratio) to * INDUCTION RULE: Patient * PRECIPITATED WITHDRAWAL|
  • | prevent IV diversion (nal- MUST be in OBJECTIVE MILD- If given before full |
  • | oxone inactive sublingually)TO-MODERATE WITHDRAWAL agonists leave receptors|
  • | (COWS SCORE >= 8 - 12) (buprenorphine displaces|
  • | prior to first dose! full agonists rapidly!).|
  • | |
  • | Methadone FULL MU-OPIOID AGONIST with * Restricted by federal law * Dose-dependent QTc |
  • | (Oral Liquid) long elimination half-life to certified Opioid Treatment prolongation and torsades|
  • | (24 - 36 hours). Programs (OTPs / daily clinic de pointes risk (ECG). |
  • | - Prevents withdrawal and dosing). * High risk of fatal |
  • | blocks illicit cravings. * Excellent for high-tolerance respiratory depression|
  • | fentanyl-exposed patients. in overdose/diversion. |
  • | |
  • | Extended-Release LONG-ACTING MU-OPIOID * Indicated for relapse * MANDATORY 7 TO 14 DAY |
  • | Naltrexone RECEPTOR ANTAGONIST. prevention post-detox. COMPLETE OPIOID-FREE |
  • | (Vivitrol IM) - Blocks subjective high * Dosing: 380 mg IM gluteal WASHOUT (verified by |
  • | from all opioid agonists. injection every 4 weeks. negative UDS and naloxone|
  • | challenge) prior to inj!|
  • +---------------------------------------------------------------------------------------------------------+
  • The Clinical Opiate Withdrawal Scale (COWS)

Assesses 11 objective and subjective parameters (resting pulse rate, sweating, restlessness, pupil size, bone/joint aches, rhinorrhea/lacrimation, GI upset, tremor, yawning, anxiety, piloerection ["gooseflesh"]).

  • Score 5–12: Mild withdrawal
  • Score 13–24: Moderate withdrawal
  • Score 25–36: Moderately severe withdrawal

Buprenorphine Induction Rule: COWS score must be ≥ 8 − 12 \ge 8-12 ≥ 8 − 12 before administering the first sublingual buprenorphine dose. Administering buprenorphine when full agonist opioids (e.g., heroin, oxycodone, fentanyl) are still bound to mu-receptors immediately displaces the full agonist due to buprenorphine's higher binding affinity, precipitating severe, agonizing precipitated withdrawal .

Universal Harm Reduction: Naloxone Co-Prescribing

Naloxone (Narcan Nasal Spray 4 mg): Rapid-acting competitive opioid receptor antagonist that reverses life-threatening opioid-induced respiratory depression within 2 to 3 minutes.

Co-Prescribing Mandate: Co-prescribe naloxone for any patient receiving chronic opioid therapy with MME ≥ 50 mg/day \text{MME} \ge 50\text{ mg/day} MME ≥ 50 mg/day , concurrent benzodiazepine prescriptions, history of substance use disorder, underlying respiratory disease (COPD/sleep apnea), or known illicit opioid use.

  • 6. Cannabis & Other Substance Use in Primary Care
  • Cannabis Hyperemesis Syndrome (CHS)

Pathophysiology: Chronic, daily, long-term consumption of high-potency tetrahydrocannabinol (THC) paradoxically downregulates enteric and central cannabinoid type 1 ( C B 1 CB_1 C B 1 ​ ) receptors and impairs hypothalamic thermoregulation, while stimulating cutaneous Transient Receptor Potential Vanilloid 1 ( TRPV1 ) nociceptors.

Clinical Presentation: Recurrent, cyclical episodes of severe intractable nausea, non-bloody vomiting, and colicky diffuse abdominal pain occurring every few weeks to months in chronic daily cannabis users.

Pathognomonic Behavioral Clue: Patients engage in compulsive, prolonged hot showering or bathing (often spending hours per day in hot water), which provides rapid, transient relief of nausea by activating cutaneous TRPV1 receptors and restoring core thermal homeostasis.

Acute & Definitive Management:

Acute Symptom Relief: Topical Capsaicin 0.075% cream applied to the periumbilical abdominal wall (activates TRPV1 receptors), IV fluid hydration, and IV Haloperidol or Droperidol (dopamine antagonists that suppress the central chemoreceptor trigger zone). Traditional antiemetics (ondansetron, promethazine) are notoriously ineffective.

Definitive Treatment: Complete and permanent cessation of all cannabis and cannabinoid products is the ONLY curative intervention. Symptoms completely resolve within 1 to 3 months of sustained abstinence.

Stimulant Use Disorder: Cocaine & Methamphetamine

Mechanism: Cocaine blocks dopamine, norepinephrine, and serotonin reuptake; methamphetamines promote massive reverse transport/release of catecholamines.

Acute Toxicity: Severe hypertension, tachyarrhythmias, hyperthermia, acute coronary vasospasm, myocardial infarction, aortic dissection, rhabdomyolysis, and acute stimulant-induced paranoid psychosis.

Clinical Rule for Acute Stimulant Chest Pain: First-line management is IV Benzodiazepines (Lorazepam) to reduce central sympathomimetic outflow, tachycardia, and coronary vasospasm. Pure beta-blockers (e.g., Propranolol) are contraindicated in acute cocaine toxicity due to theoretical unopposed alpha-1 adrenergic vasoconstriction worsening hypertension and coronary ischemia.

7. Geriatric Considerations in Substance Use

The "Invisible Epidemic": Substance misuse in older adults is frequently under-identified because symptoms (falls, cognitive decline, insomnia, malnutrition, self-neglect) are erroneously attributed to normal aging or dementia.

Altered Pharmacokinetics: Due to age-related reductions in total body water, increased relative body fat, reduced hepatic blood flow/CYP450 clearance, and declining GFR, older adults achieve higher peak blood alcohol and drug concentrations with prolonged elimination half-lives.

Dangerous Drug Interactions: Alcohol combined with antihypertensives causes severe orthostatic hypotension and syncope; combined with sedatives/hypnotics or opioids causes fatal respiratory depression; combined with acetaminophen causes accelerated hepatotoxicity; and combined with warfarin increases INR and life-threatening gastrointestinal bleeding.

8. Board-Yield Summary & Clinical Pearls +-----------------------------------------------------------------------------+

  • | ANCC AGPCNP CLINICAL EXAM PEARLS |
  • | |
  • | * Alcohol Withdrawal in Cirrhosis / Liver Failure -> USE ONLY "LOT" |
  • | BENZODIAZEPINES (Lorazepam, Oxazepam, Temazepam) because they bypass |
  • | Phase I CYP oxidation. Avoid Diazepam/Chlordiazepoxide! |
  • | |
  • | * Thiamine BEFORE Glucose -> ALWAYS administer IV Thiamine (100-500 mg) |
  • | BEFORE or CONCURRENTLY with IV Dextrose to prevent precipitating acute |
  • | irreversible Wernicke Encephalopathy / Korsakoff syndrome. |
  • | |
  • | * AUD Relapse Prevention in Cirrhosis / Liver Disease -> ACAMPROSATE is |
  • | the drug of choice (100% renal elimination). Naltrexone is CONTRA- |
  • | INDICATED in liver failure / acute hepatitis or concurrent opioid use. |
  • | |
  • | * Buprenorphine Induction -> Patient MUST be in mild-to-moderate withdrawal|
  • | (COWS score >= 8-12) before the first dose to prevent PRECIPITATED |
  • | WITHDRAWAL. |
  • | |
  • | * Cannabis Hyperemesis Syndrome -> Cyclical vomiting relieved by HOT |
  • | SHOWERS in a chronic daily cannabis user. Treat acutely with TOPICAL |
  • | CAPSAICIN cream and Haloperidol; definitive cure is TOTAL CANNABIS STOP.|
  • | |
  • | * Smoking Cessation -> VARENICLINE is the most effective single agent. |
  • | COMBINATION NRT (Patch + Gum/Lozenge) is superior to single-agent NRT. |
  • | BUPROPION is contraindicated in seizure disorders and eating disorders. |
  • +-----------------------------------------------------------------------------+